Director Nancy C. Andrews filed a Form 4 with the SEC on August 20, 2026, reporting transactions in Charles River Laboratories International, Inc. common stock that occurred on August 18, 2026.
Key Highlights
- Reporting person: Nancy C. Andrews, identified as a Director of Charles River Laboratories International, Inc. (NYSE:CRL)
- Option exercise: 573 shares of common stock acquired via an "M" (exercise of in-the-money or at-the-money derivative) transaction at $164.30 per share on August 18, 2026
- Shares sold: 573 shares of common stock disposed of via an "S" (sale) transaction at $285.24 per share on August 18, 2026
- Direct ownership after transactions: 1,438 shares of common stock held directly
- Indirect ownership: 3,964 shares of common stock held indirectly by trust
- Stock options exercised to zero: The stock options exercised carried an exercise price of $164.30, with an expiration date of March 2, 2027, and 0 options remain following the transaction
Nancy C. Andrews Option Exercise and Sale of CRL Common Stock
According to the filing, Director Nancy C. Andrews exercised stock options on August 18, 2026, acquiring 573 shares of Charles River Laboratories International, Inc. common stock at an exercise price of $164.30 per share. The options exercised were originally exercisable beginning March 2, 2021, and were set to expire March 2, 2027. Following the exercise, the filing reports that 0 stock options remain outstanding in Andrews's name.
On the same date, the filing discloses that Andrews disposed of 573 shares of common stock at a price of $285.24 per share through an open-market sale. Following both transactions, Andrews directly held 1,438 shares of common stock. The filing also reports 3,964 shares held indirectly through a trust, which were not subject to the reported transactions.
The Form 4 was filed as an individual report by one reporting person. No indication is provided in the filing that the transactions were made pursuant to a Rule 10b5-1(c) trading plan, as the relevant checkbox was not marked.
What Was Disclosed
The filing reports a same-day option exercise and sale of 573 shares of Charles River Laboratories common stock by Director Nancy C. Andrews on August 18, 2026. After the transactions, Andrews directly held 1,438 shares and indirectly held 3,964 shares through a trust.




Please wait processing your request...